Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 24Fallopian Tube Neoplasms 13Neoplasms 11Breast Neoplasms 11Triple Negative Breast Neoplasms 5Carcinoma, Ovarian Epithelial 5Solid Tumors 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Lymphoma 3Carcinoma 3Sarcoma, Kaposi 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Advanced Solid Tumors 2AIDS-related Kaposi sarcoma 2Urinary Bladder Neoplasms 1Unrecognized Condition 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1

Interventions

Cyclophosphamide 8Vincristine 6romidepsin 5Prednisone 5Doxorubicin 5Lenalidomide 4Etoposide 4fludarabine phosphate 3fludarabine 3Rituximab 3Dexamethasone 3Bortezomib 3Azacitidine 3selinexor 2darinaparsin 2carfilzomib 2belinostat 2Oxaliplatin 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Injections 2Gemcitabine 2Depsipeptides 2Dasatinib 2Carboplatin 2Brentuximab Vedotin 2Biopsy 2Bendamustine Hydrochloride 2Alemtuzumab 2umbralisib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Peripheral × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡